THE EFFECT OF SUPEROXIDE DISMUTASE ON SKIN CONDITION AND QUALITY OF LIFE IN TOPICAL THERAPY IN PATIENTS WITH BULLOUS EPIDERMOLYSIS
DOI:
https://doi.org/10.32689/2663-0672-2021-1-12Keywords:
superoxide dismutase, Sodermix, skin diseases, bullous epidermolysis, pain, self-esteem, quality of lifeAbstract
Abstract. Formulation of the problem. Bullous epidermolysis (BE) is a genetically and clinically heterogeneous disease characterized by the formation of blisters and erosions on the skin and mucous membranes due to even very slight mechanical friction or injury. According to the international classification adopted in 2008, BE has four forms depending on the level of damage to the epidermis: simple, borderline, dystrophic and Kindler's syndrome. Clinical manifestations of PE have a very negative impact on the self-assessment of the quality of life of a young patient and his family members not only physically but also psychologically. Formulation of the purpose of the article. The aim is to evaluate the effectiveness of topical use of the enzyme superoxide dismutase in the form of a cream on the condition of the skin and to assess the quality of life of patients with bullous epidermolysis. Analysis of recent research and publications. An important area of research is the search for effective ways to improve the quality of life of patients with bullous epidermolysis. Materials and methods of research. The work was performed at the Department of Dermatology and Venereology with a course in cosmetology of NMU named after OO Bogomolets and with the support of the center "Debra-Ukraine". In order to objectify the assessments of the real therapeutic effect of superoxide dismutase in patients with bullous epidermolysis, we used the assessment of the condition of the skin and automated testing of quality of life in the dynamics before and after drug use. Research results. A combined study of the therapeutic effect of weeks of local treatment of affected skin areas in patients with BE with Sodermix (Life Science Investments). Discussion. The therapeutic effect of the drug is provided by the high content of Superoxide dismutase (SOD), which destroys free radicals that occur during physiological metabolism, thereby improving the condition of the skin and subjective feelings of patients. Conclusions and prospects for further research. It has been proven that treatment with superoxide dismutase helps to improve the condition of the skin of patients with bullous epidermolysis, which mediates the positive effect of the drug on the quality of life of these patients.
References
Boeira V. L., Souza E. S., Rocha B. de O. et al. Inherited epidermolysis bullosa: clinical and therapeutic aspects. An. Bras. Dermatol. 2013. Vol. 88. Issue 2. P. 185–198. DOI: 10.1590/S0365-05962013000200001.
Bornert O., Hogervorst M., Nauroy P. et al. QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: a preclinical study. J Invest Dermatol. 2021. Vol. 141. Issue 4. P. 883–893.
De Rosa L., Secone Seconetti A., De Santis G. et al. Laminin 332- dependent YAP dysregulation depletes epidermal stem cells in junctional epidermolysis bullosa. Cell Rep. 2019. Vol. 27. P. 2036–2049.
Fine J. D., Eady R. A., Bauer E. A. et al. Revised classification system for inherited epidermolysis bullosa: report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad Dermatol. 2000. Vol. 42. P. 1051–1066.
Graham, T., Sooriah, S., Giampieri, S., Box, R., & Grocott, P. (2019), Iterative codesign and testing of a novel dressing glove for epidermolysis bullosa. Journal of wound care. Vol. 28. Issue 1. P. 5–14.
Haik J., Kornhaber R., Blal B., & Harats M. The feasibility of a handheld electrospinning device for the application of nanofibrous wound dressings. Advances in wound care. 2017. Vol. 6. Issue 5. P. 166–174.
Has C., Liu L., Bolling M. et al. Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. Br J Dermatol. 2020. Vol. 182. P. 574–592.
Has C. Chronic tissue damage: a common pathomechanism of genodermatoses. Br J Dermatol. 2019. Vol. 181. P. 440–441.
Fine J-D., Hintner H. Epidermolysis bullosa (translated from English by Yu. Yu. Kotalevskaya). M.: Practice, 2014. 358 p. (Ru)
Kariminejad A., Vahidnezhad H., Ghaderi-Sohi S. et al. Widespread aplasia cutis congenita in sibs with PLEC1 and ITG B4 variants. Am J Med Genet A. 2019. Vol. 179. P. 1547–1555.
Mae R.-Q., Dédée F. M. Managing epidermolysis bullosa during the COVID-19 pandemic: experience and ideals. Clinics in Dermatology. 2021. DOI: 10.1016/j.clindermatol.2021.01.014.
Mariath L. M., Santin J. T., Schuler-Faccini L. & Kiszewski A. E. Inherited epidermolysis bullosa: update on the clinical and genetic aspects. An Bras Dermatol. 2020. Vol. 95. P. 551–569.
Nguyen H. C., Nguyen M. H., Do B. N. et al. People with suspected COVID-19 symptoms were more likely depressed and had lower health-related quality of life: the potential benefit of health literacy. J Clin Med. 2020. Vol. 9. Issue 4. 965 p.
Pope E., Lara-Corrales I., Mellerio J. et al. A consensus approach to wound care in epidermolysis bullosa. J Am Acad Dermatol. 2012. Vol. 67. Issue 5. P. 904–917.
Qurrat Ul Ain, Estefania V. R., Campos E. V. et al. Gene Delivery to the Skin – How Far Have We Come? Trends in Biotechnology. 2020. Vol. 39. Issue 5. P. 474–487.
Reimer A., Hess M., Schwieger-Briel A. et al. Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study. Br J Dermatol. 2020. Vol. 182. P. 1437–1448.
Takashima, S., Shinkuma, S., Fujita, Y., et al. (2019), Efficient gene reframing therapy for recessive dystrophic epidermolysis bullosa with CRISPR/Cas9. Journal of Investigative Dermatology. Vol. 139. Issue 8. P. 1711–1721.
Suresh H. Assessment of health-related quality of life using EQ-5D among residents of mysore during the coronavirus disease pandemic. Ann Commun Health. 2021. Vol. 9. P. 127–132.
Zurab Siprashvili, Ngon T. Nguyen, Emily S. Gorell et al. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa. JAMA. 2016. Vol. 316. Issue 17. P. 1808–1817. DOI: 10.1001/jama.2016.15588.
